1. Market Research
  2. > Pharmaceutical
  3. > Drug Development Market Trends
  4. > Drug Development Analysis & Statistics in Japan, June 2019

Drug Development Analysis & Statistics in Japan, June 2019

1-30 of 50 reports

Global High Content Screening (HCS) Industry

Global High Content Screening (HCS) Industry

  • $ 5600
  • Industry report
  • May 2019

This report analyzes the worldwide markets for High Content Screening (HCS) in US$ Million.The Global market is further analyzed by the following Segments: Consumables, Instruments, and Others. The report ...

  • Industries : Drug Development
  • Countries : World, Europe, APAC, United States, Japan
2019 Global Therapeutic Drug Monitoring (TDM) Market: US, Europe, Japan--US, Europe, Japan--Supplier Shares, Test Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review

2019 Global Therapeutic Drug Monitoring (TDM) Market: US, Europe, Japan--US, Europe, Japan--Supplier Shares, Test Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review

  • $ 2700
  • Industry report
  • April 2019

2019 Global Therapeutic Drug Monitoring (TDM) Market: US, Europe, Japan--US, Europe, Japan--Supplier Shares, Test Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation ...

  • Industries : Drug Development
  • Countries : World, United States, Europe, Japan
2019 Japanese Encephalitis Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

2019 Japanese Encephalitis Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • $ 1799
  • Industry report
  • April 2019

The global clinical trial report- “2019 Japanese Encephalitis Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Japanese Encephalitis. It presents in-depth ...

  • Industries : Pathology, Drug Development
  • Countries : Japan
Chronic Kidney Disease-Mineral Bone Disorders (CKD-MBD): Competitive Landscape to 2027

Chronic Kidney Disease-Mineral Bone Disorders (CKD-MBD): Competitive Landscape to 2027

  • $ 3495
  • Industry report
  • March 2019

Chronic Kidney Disease-Mineral Bone Disorders (CKD-MBD): Competitive Landscape to 2027SummaryCKD-MBD is an umbrella term used to link renal osteodystrophy with mineral bone disorders and bone pathology ...

  • Industries : Drug Development, Pharmaceutical
  • Countries : United States, Japan, World, East Asia
2019 Japanese Encephalitis Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

2019 Japanese Encephalitis Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

  • $ 2199
  • Industry report
  • February 2019

The ongoing clinical trial research report- “2019 Japanese Encephalitis Ongoing Clinical Trials Study” analyzes the current scenario of all active Japanese Encephalitis trials across the world. The ...

  • Industries : Pathology, Drug Development
  • Countries : Japan
Therapeutic Drug Monitoring (TDM), 2019-2023: US, Europe, Japan--Supplier Shares and Strategies, Volume and Sales Segment Forecasts

Therapeutic Drug Monitoring (TDM), 2019-2023: US, Europe, Japan--Supplier Shares and Strategies, Volume and Sales Segment Forecasts

  • $ 5500
  • Industry report
  • February 2019

Therapeutic Drug Monitoring (TDM), 2019-2023: US, Europe, Japan--Supplier Shares and Strategies, Volume and Sales Segment ForecastsThis new 313-page report contains 83 tables and provides analysis of the ...

  • Industries : Drug Development
  • Countries : World, United States, Europe, Japan
Glaucoma: Competitive Landscape to 2026

Glaucoma: Competitive Landscape to 2026

  • $ 3495
  • Industry report
  • December 2018

Glaucoma: Competitive Landscape to 2026SummaryWith no new classes of drugs having been developed for the treatment of glaucoma in the last twenty years, the focus of pharmaceutical companies has begun ...

  • Industries : Health Services, Drug Development, Pharmaceutical, Pathology, Healthcare
  • Countries : United States, Japan, World, China
Age-Related Macular Degeneration: Competitive Landscape to 2026

Age-Related Macular Degeneration: Competitive Landscape to 2026

  • $ 3495
  • Industry report
  • December 2018

Age-Related Macular Degeneration: Competitive Landscape to 2026SummaryThe Age-Related Macular Degeneration (AMD) market has been dominated by big pharma companies and their pipeline candidates are ensuring ...

  • Industries : Drug Development, Pharmaceutical
  • Countries : United States, World, Japan
TransGenic Inc (2342) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

TransGenic Inc (2342) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • December 2018

SummaryTransGenic Inc (TransGenic) is a biotechnology company which develops and distributes genetically engineered animals and antibodies and licensing of these activities.The products and services of ...

  • Industries : Pharmaceutical, Drug Development
  • Countries : Japan
2019-2023 Global Therapeutic Drug Monitoring (TDM): US, Europe, Japan--Market Share Analysis, Country Segment Forecasts, Competitive Intelligence, Technology Trends, Opportunities for Suppliers

2019-2023 Global Therapeutic Drug Monitoring (TDM): US, Europe, Japan--Market Share Analysis, Country Segment Forecasts, Competitive Intelligence, Technology Trends, Opportunities for Suppliers

  • $ 4500
  • Industry report
  • December 2018

2019-2023 Global Therapeutic Drug Monitoring (TDM): US, Europe, Japan--Market Share Analysis, Country Segment Forecasts, Competitive Intelligence, Technology Trends, Opportunities for SuppliersDuring the ...

  • Industries : Drug Development
  • Countries : World, United States, Europe, Japan
3-D Matrix Ltd (7777) - Product Pipeline Analysis, 2018 Update

3-D Matrix Ltd (7777) - Product Pipeline Analysis, 2018 Update

  • $ 750
  • Company report
  • November 2018

Summary3-D Matrix Ltd (3-D Matrix) is a regenerative medicine company that focuses at commercializing its self-assembling peptide technology. It develops medical products by applying this technology unde ...

  • Industries : Medical Supply, Drug Development
  • Countries : Japan, Australia, Australasia
JCR Pharmaceuticals Co Ltd (4552) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

JCR Pharmaceuticals Co Ltd (4552) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • November 2018

SummaryJCR Pharmaceuticals Co Ltd (JCR) manufactures, sells, buys, imports and exports pharmaceutical products.It provides biopharmaceuticals in the field of regenerative medicine for the treatment of ...

  • Industries : Pharmaceutical
  • Countries : Japan
NovAliX SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile

NovAliX SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • November 2018

SummaryNovAliX SAS (NovAliX) is a contract research organization that offers outsourcing and insourcing research services for drug discovery.The organization provides chemical biology services such as ...

  • Industries : Drug Development, Pharmaceutical
  • Countries : France, United States, Japan
Adempas

Adempas

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewAdempas (riociguat; Bayer/Merck and Co) is a first-in-class drug that activates soluble guanylyl cyclase (sGC), a key enzyme in nitric oxide-mediated vasodilation of vascular smooth muscle ...

  • Industries : Drug Development
  • Countries : United States, Japan, European Union
Allergies Global Clinical Trials Review, H2, 2018

Allergies Global Clinical Trials Review, H2, 2018

  • $ 2500
  • Industry report
  • October 2018

Allergies Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Allergies Global Clinical Trials Review, H2, 2018" provides an overview of Allergies clinical trials scenario.This ...

  • Industries : Pharmaceutical, Drug Development, Medical Biotechnology
  • Countries : World, Japan
Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018

  • $ 3500
  • Company report
  • October 2018

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018SummaryAccording ...

  • Industries : Pathology, Pharmaceutical, Therapy, Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : Japan, Brazil, World, United States, Canada
Sosei Group Corp (4565) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Sosei Group Corp (4565) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • October 2018

SummarySosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs.The company’s pipeline products include NorLevo, NVA237, QVA149 and SO-1105.Its NorLevo product is ...

  • Industries : Therapy, Pharmaceutical
  • Countries : Japan
CMIC Holdings Co Ltd (2309) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

CMIC Holdings Co Ltd (2309) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • October 2018

SummaryCMIC Holdings Co Ltd (CMIC) is a contract research organization that supports drug development services.The organization offers medical research related services to pharmaceuticals and medical ...

  • Industries : Pharmaceutical, Drug Development
  • Countries : Japan
Cardiovascular Systems Inc (CSII) - Product Pipeline Analysis, 2018 Update

Cardiovascular Systems Inc (CSII) - Product Pipeline Analysis, 2018 Update

  • $ 750
  • Company report
  • October 2018

SummaryCardiovascular Systems Inc (CSI) is a medical device company that develops and commercializes products for the treatment of peripheral and coronary vascular disease.The company’s products include ...

  • Industries : Health Services
  • Countries : United States, Japan
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2018

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2018

  • $ 3500
  • Company report
  • September 2018

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2018SummaryAccording to the recently published report ’Transmembrane Prolyl ...

  • Industries : Pathology, Chronic Disease, Pharmaceutical
  • Countries : World, Japan, China, United States, East Asia
JRI Orthopaedics Ltd - Product Pipeline Analysis, 2018 Update

JRI Orthopaedics Ltd - Product Pipeline Analysis, 2018 Update

  • $ 750
  • Company report
  • September 2018

SummaryJRI Orthopaedics Ltd (JRI) a subsidiary of Orthopaedic Research UK (ORUK), is a manufacturer of orthopaedic implants and surgical instruments.The company develops products for joint replacement, ...

  • Industries : Orthopedics, Medical Device
  • Countries : United Kingdom, Japan, China, World
Mekinist

Mekinist

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewMekinist (trametinib; Novartis/Japan Tobacco) is a selective allosteric inhibitor of the MEK1 and MEK2 enzymes in the mitogen-activated protein kinase (MAPK) pathway. MEK1 and MEK2 are dual-specificity ...

  • Industries : Drug Development
  • Countries : Japan, United States, European Union
Axial Spondyloarthritis (AxSpA): Competitive Landscape to 2026

Axial Spondyloarthritis (AxSpA): Competitive Landscape to 2026

  • $ 3495
  • Industry report
  • June 2018

Axial Spondyloarthritis (AxSpA): Competitive Landscape to 2026SummaryAxial Spondyloarthritis (AxSpA) is a chronic, immune-mediated inflammatory disease of the axial skeleton (sacroiliac joints and spine). ...

  • Industries : Medical Biotechnology, Drug Development, Pharmaceutical, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, World, Japan
Pollen Allergy Global Clinical Trials Review, H1, 2018

Pollen Allergy Global Clinical Trials Review, H1, 2018

  • $ 2500
  • Industry report
  • May 2018

Pollen Allergy Global Clinical Trials Review, H1, 2018SummaryGlobalData’s clinical trial report, “Pollen Allergy Global Clinical Trials Review, H1, 2018" provides an overview of Pollen Allergy clinical ...

  • Industries : Pharmaceutical, Chronic Disease, Medical Biotechnology, Drug Development, Pathology, Therapy
  • Countries : World, Japan
CellSeed Inc (7776) - Product Pipeline Analysis, 2018 Update

CellSeed Inc (7776) - Product Pipeline Analysis, 2018 Update

  • $ 750
  • Company report
  • May 2018

SummaryCellSeed Inc (CellSeed) is a biotechnology company that develops and offers solutions for tissue-engineering through novel cell harvest methods.The company’s products include epithelial cell sheet ...

  • Industries : Drug Development
  • Countries : Japan
Impetigo - Pipeline Review, H1 2018

Impetigo - Pipeline Review, H1 2018

  • $ 2000
  • Company report
  • May 2018

Impetigo - Pipeline Review, H1 2018SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Impetigo - Pipeline Review, H1 2018, provides an overview of the Impetigo ...

  • Industries : Therapy, Pathology, Pharmaceutical, Healthcare
  • Countries : United States, World, Canada, Japan
Osteoporosis: Global Drug Forecast and Market Analysis to 2027

Osteoporosis: Global Drug Forecast and Market Analysis to 2027

  • $ 10995
  • Industry report
  • April 2018

Osteoporosis: Global Drug Forecast and Market Analysis to 2027SummaryGlobal Osteoporosis pharmaceutical market in 2017 was $7.4B, including both branded and generic products. The branded market accounted ...

  • Industries : Chronic Disease, Pathology, Therapy, Pharmaceutical
  • Countries : World, United States, Japan
Methicillin-Resistant Staphylococcus aureus (MRSA): Competitive Landscape to 2026

Methicillin-Resistant Staphylococcus aureus (MRSA): Competitive Landscape to 2026

  • $ 3495
  • Industry report
  • March 2018

Methicillin-Resistant Staphylococcus aureus (MRSA): Competitive Landscape to 2026SummaryMethicillin-resistant Staphylococcus aureus (MRSA) is a widespread Gram-positive bacterium spread through direct ...

  • Industries : Drug Development, Pharmaceutical, Healthcare
  • Countries : United States, Japan, World
Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2026

Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2026

  • $ 10995
  • Industry report
  • March 2018

Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2026SummaryThe recent surge in investment in Head and Neck Squamous Cell Carcinoma (HNSCC) has resulted in an innovative pipeline. ...

  • Industries : Therapy, Oncology, Cancer, Pathology, Pharmaceutical
  • Countries : United States, Japan
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H1 2018

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H1 2018

  • $ 3500
  • Company report
  • March 2018

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H1 2018SummaryTransmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Facto ...

  • Industries : Pathology, Chronic Disease, Pharmaceutical
  • Countries : China, Japan, United States, East Asia, World

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on